QUERSUS AND AUDI COMBINE UNIQUE MOTORSPORT DESIGN WITH FUTURISTIC ERGONOMIC CHAIRS
August 30, 2024 – Quersus, one of the leading European ergonomic chair manufacturers, proudly announces an exceptional collaboration with Audi, the renowned German premium car manufacturer. Together, they present two exclusive Quersus models under the Audi license: the Quersus VAOS Audi RS Q e-tron and the Quersus ICOS Audi. These chairs embody the essence of innovation and design, combining superior comfort with cutting-edge automotive aesthetics.
Cutting-Edge Designs inspired by Audi
The Quersus VAOS Audi Gaming Chair: Inspired by the design of the Audi RS Q e-tron, victorious in the 2024 Dakar Rally, this gaming chair reflects the spirit of competition and advanced technology. Its bold lines echo the dynamic design of Audi's off-road prototype vehicle.
The Quersus ICOS Audi Office Chair: Inspired by the design of the Audi single-seater study, this ergonomic hybrid office chair with a sporty curve embodies the innovation and pursuit of performance of Audi vehicles. Its modern design, blending sobriety and character, revolutionizes the look of any workspace.
Heading towards the future
The Quersus Audi chairs are made from premium materials, they reflect Audi's quality standards and our commitment to offering extremely durable products, contributing to reducing the frequent renewal of office supplies and minimizing environmental impact. This approach also extends to the packaging, designed with recycled materials.
Exceptional comfort and ergonomics
Quersus chairs provide exceptional support thanks to multiple ergonomic features, such as 4- directional lumbar support, state-of-the-art memory foam, and multiple adjustment options for the backrest and seat. This advanced ergonomic design, the result of years of work and innovation, allows prolonged use without compromising on comfort, enhancing productivity and user health.
More info & photos in the press kit: https://bit.ly/quersusxaudi
Keywords
Contacts
Martin.Steinbach@fleaky.de
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships14.1.2025 13:05:41 CET | Press Release
Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies. The Patch Forward Prize, part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. Each of the prizes announced today represents an award of US$ 2 million, that will be shared between LTS and its partners. The awarded projects bring together LTS’s proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech man
FEV develops AI-supported driver monitoring system CogniSafe9.1.2025 11:00:00 CET | Pressmeddelande
Aachen – FEV, a leading global innovation driver for the mobility of tomorrow, presents CogniSafe, a state-of-the-art Driver Monitoring System (DMS) that significantly increases road safety. The system uses advanced technologies such as deep learning and computer vision to monitor driver conditions such as distraction, fatigue and inattention in real time and under even the most challenging conditions.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 10:25:56 CET | Press Release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can
175 years of Heidelberger Druckmaschinen: Company starts anniversary year with growth strategy8.1.2025 13:11:11 CET | Press Release
Growth strategy: medium-term sales potential of more than € 300 million Growth drivers in the core business: packaging, digital printing Software and lifecycle business Industrial business: focus on further expansion 175 years: the company has been shaping the printing industry for decades with technological innovations, quality and reliability Numerous anniversary activities throughout the year
Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality7.1.2025 08:16:33 CET | Press Release
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom